Announcements Trials
Browse Landscape

Status

Available 2Approved for marketing 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 303Observational 70Expanded_access 3

Sponsor

Cancer Type

Head & Neck 5Thoracic 4Gastrointestinal 3CNS 3Genitourinary 2Gynecologic 1Dermatologic 1Breast 1

Conditions

Pancreatic Neoplasms 14Colorectal Neoplasms 10Carcinoma, Hepatocellular 9Gastrointestinal Stromal Tumors 7Carcinoma, Non-Small-Cell Lung 7Stomach Neoplasms 6Ovarian Neoplasms 6Liver Neoplasms 6Cholangiocarcinoma 6Prostatic Neoplasms 5Breast Neoplasms 5Melanoma 4Sarcoma 3Head and Neck Neoplasms 3Gastrointestinal Neoplasms 3Colonic Neoplasms 3Carcinoma, Squamous Cell 3Neuroblastoma 2Neoplasms 2Hepatoblastoma 2Glioblastoma 2Esophageal Neoplasms 2Endometrial Neoplasms 2Carcinoma, Renal Cell 2Wounds and Injuries 1Wilms Tumor 1Uveal Melanoma 1Uterine Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1

Interventions

zenocutuzumab 1ulixertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Expanded_access × Head and Neck Neoplasms × Gastrointestinal × Clear all
NCT04566393 2026-06-04

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

xCures

Available
CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Glioblastoma, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT06872489 2025-07-23

Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors

Second Life Therapeutics

Available
CNSGastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Neuroblastoma, Pancreatic Neoplasms, Recurrence

NCT04100694 2025-05-20

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

Merus B.V.

Approved for marketing
BreastGastrointestinalGenitourinaryHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Neoplasms, Unknown Primary, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡